Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02599454 · ClinicalTrials.gov registry record · Phase 1
Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer
A Phase 1 study of Stage I Non-Small Cell Lung Cancer, sponsored by Megan Daly, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT02599454: Completed Phase 1 study of Stage I Non-Small Cell Lung Cancer, sponsored by Megan Daly, MD.
NCT02599454 is a Phase 1 study of Stage I Non-Small Cell Lung Cancer that has completed, run by Megan Daly, MD. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02599454, a Phase 1 study of Stage I Non-Small Cell Lung Cancer, has completed, sponsored by Megan Daly, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase I trial studies the side effects and best dose of atezolizumab that can be given together with stereotactic body radiation therapy (SBRT) in treating patients with stage I non-small cell lung cancer that cannot be removed by surgery. Monoclonal antibodies, such as atezolizumab, may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Stereotactic body radiation therapy is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue. Giving atezolizumab together with stereotactic body radiation therapy may kill more tumor cells and be a better treatment for non-small cell lung cancer that cannot be removed by surgery.
Primary Outcome
The adverse events will be summarized as frequency, proportion of patients MTD. The exact 95% confidence interval for proportion will be categorized by type, severity, nadir or maximum values for the laboratory measures, time of onset, duration, and reversibility or outcome. Tables will be created to summarize these toxicities by dose and course.
Conditions Studied
Interventions
- DRUG Atezolizumab
- RADIATION Stereotactic Body Radiation Therapy
Study Locations (2)
California
- University of California Davis Comprehensive Cancer Center - Sacramento
- David Grant United States Air Force Medical Center - Travis AFB
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-04-26 |
| Est. Completion | 2024-02-20 |
| Phase | Phase 1 |
What the finished NCT02599454 record still lists
NCT02599454 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Stage I Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Atezolizumab is the first listed.
NCT02599454 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02599454 about?
NCT02599454 is a clinical study titled "Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer". This phase I trial studies the side effects and best dose of atezolizumab that can be given together with stereotactic body radiation therapy (SBRT) in treating patients with stage I non-small cell lung cancer that cannot be removed by surgery. Monoclonal antibodies, such as atezolizumab, may interf...
What is the current status of trial NCT02599454?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2018-04-26. Estimated completion is 2024-02-20.
What conditions does trial NCT02599454 study?
This clinical trial studies the following conditions: Stage I Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT02599454?
The interventions under investigation include: Atezolizumab (DRUG), Stereotactic Body Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT02599454?
This trial is sponsored by Megan Daly, MD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02599454 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage I Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02599454's enrollment target sits among peer trials
20 1629th of 2000 higher than 285 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI